Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Breast05
jRCT2061230102Phase 3Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of datopotamab deruxtecan, durvalumab, pembrolizumab, paclitaxel, gemcitabine and 1 more in triple-negative breast cancer (TNBC) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Progression-free survival. Started May 2024; status: recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on jRCT2061230102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230102.